Background
Methods
Study design and patient populations
Endpoints and assessments
Statistical analyses
Results
Patients
Pooled, PBO-controlled studies [16] | ABPM study [17] | |||||
---|---|---|---|---|---|---|
Characteristica
| PBO (n = 646) | CANA 100 mg (n = 833) | CANA 300 mg (n = 834) | PBO (n = 56) | CANA 100 mg (n = 57) | CANA 300 mg (n = 56) |
Sex, n (%) | ||||||
Male | 334 (52) | 408 (49) | 404 (48) | 33 (59) | 34 (60) | 31 (55) |
Female | 312 (48) | 425 (51) | 430 (52) | 23 (41) | 23 (40) | 25 (45) |
Age, years | 56.3 (9.8) | 55.9 (10.1) | 55.7 (9.5) | 59.6 (9.5) | 57.8 (8.7) | 58.3 (6.9) |
Race, n (%)b
| ||||||
White | 470 (73) | 591 (71) | 610 (73) | 46 (82) | 45 (79) | 43 (77) |
Black or African American | 28 (4) | 43 (5) | 48 (6) | 9 (16) | 10 (18) | 12 (21) |
Asian | 82 (13) | 103 (12) | 100 (12) | 0 | 1 (2) | 1 (2) |
Otherc
| 66 (10) | 96 (12) | 76 (9) | 1 (2) | 1 (2) | 0 |
HbA1c, % | 8.0 (0.9) | 8.0 (0.9) | 8.0 (1.0) | 8.2 (0.9) | 8.1 (0.9) | 8.0 (0.8) |
BMI, kg/m2
| 31.9 (6.4) | 32.3 (6.4) | 32.0 (6.5) | 32.9 (5.7) | 33.0 (6.0) | 34.1 (6.8) |
eGFR, mL/min/1.73 m2
| 87.0 (19.8) | 88.3 (19.0) | 88.8 (18.9) | 87.9 (18.3) | 87.2 (20.3) | 85.6 (19.7) |
Duration of T2DM, years | 7.5 (6.2) | 7.2 (5.8) | 7.4 (6.2) | 11.8 (8.7) | 9.4 (6.0) | 10.3 (6.2) |
Seated SBP, mmHg | 128.5 (13.2) | 128.0 (12.8) | 128.8 (12.8) | 137.7 (8.6) | 138.5 (11.1) | 139.2 (8.8) |
Seated DBP, mmHg | 77.9 (8.3) | 77.5 (8.0) | 78.2 (8.3) | 82.7 (8.6) | 82.4 (7.7) | 83.0 (8.2) |